Medindia

X

Reportlinker Adds Cephalon Inc.: PharmaVitae Profile

Wednesday, February 17, 2010 Press Release J E 4
Advertisement


NEW YORK, Feb. 16 Reportlinker.com announces that a new market research report is available in its catalogue:

Cephalon Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0177570/Cephalon-Inc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Cephalon in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Cephalon's performance against key rivals in the prescription pharmaceutical sector

*Discover the impact of genericization of Provigil and assess the effectiveness of the company's lifecycle management strategy to cope with this

*Assess the increasing importance of emerging therapy areas, particularly oncology and the drug Treanda, in order to sustain growth

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Cephalon: PharmaVitae forecasts at a glance 8

Strategic insight 9

Strong growth from Provigil and Actiq makes Cephalon a CNS-centric player 9

Generic sales erosion of key products only slightly offset by product lifecycle management strategies 9

Cephalon's lifecycle management strategy: generics have the final word 9

The CNS therapy area is one undergoing significant generic sales erosion 12

Cephalon acquires in order to diversify 13

SWOT analysis 16

Table of Contents 17

Table of figures 19

Chapter 3 Quarterly news update 20

Product developments 20

Deals and alliances 22

Product deals 22

Technology deals 23

M&A activity 24

Company announcements 25

Future product milestones 26

Chapter 4 Company introduction 27

Key findings 27

Background 28

Key corporate developments 28

M&A history 28

CIMA Labs: a story of lifecycle management 28

Salmedix: branching out into oncology 28

Zeneus Holdings: gaining a foothold into Europe 28

Product acquisitions: Amrix, developing a new therapeutic interest 29

Acquisitive year in 2009 29

Chapter 5 Company sales 31

Key findings 31

Prescription pharmaceutical sales and growth rate analysis, 2002-14 32

Product analysis 33

Product analysis, 2002-08 35

Product analysis, 2008-14 37

Therapy area analysis 40

Geographic analysis 42

Launch/core/expiry analysis 44

Explanation of launch/core/expiry analysis 44

Launch analysis, 2008-14 45

Core analysis, 2008-14 46

Expiry analysis, 2008-14 47

Launch/core/expiry configuration, 2008-14 48

Molecule type analysis 49

Externalization analysis 51

Chapter 6 Company financials 53

Key findings 53

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 54

Operating costs and profit analysis 55

Operating costs and profit analysis, 2002-08 56

Operating cost ratio and profit margin analysis, 2002-08 57

Operating cost ratio and profit margin analysis, 2008-14 58

Operating costs and profit analysis, 2008-14 59

Chapter 7 Key products and competitors 60

Key findings 60

Overview 61

Central nervous system 62

Provigil 62

Overview 62

Sales forecast 63

Nuvigil 65

Overview 65

Sales forecast 66

Actiq 68

Overview 68

Sales forecast 69

Fentora 71

Overview 71

Sales forecast 72

Subsection 1 72

Oncology 74

Treanda 74

Overview 74

Sales forecast 75

Chapter 8 Appendix 77

Abbreviations 77

About Datamonitor 78

About Datamonitor Healthcare 78

Datamonitor consulting 78

Disclaimer 80

List of Tables

Table 1: Cephalon - PharmaVitae forecasts at a glance 8

Table 2: Cephalon key product developments, 2009 20

Table 3: Cephalon product deals and alliances, 2009 22

Table 4: Cephalon technology deals and alliances, 2009 23

Table 5: Cephalon M&A activity, 2009 24

Table 6: Cephalon company announcements, 2009 25

Table 7: Cephalon future product milestones, 2009-11 26

Table 8: Cephalon product portfolio overview ($m), 2002-08 35

Table 9: Cephalon product portfolio overview ($m), 2008-14 37

Table 10: Cephalon prescription pharmaceutical sales by therapy area ($m), 2008-14 41

Table 11: Cephalon prescription pharmaceutical sales by geographic region ($m), 2008-14 43

Table 12: Cephalon launch portfolio overview ($m), 2008-14 45

Table 13: Cephalon core portfolio overview ($m), 2008-14 46

Table 14: Cephalon expiry portfolio overview ($m), 2008-14 47

Table 15: Cephalon prescription pharmaceutical sales by molecule type ($m), 2008-14 50

Table 16: Cephalon prescription pharmaceutical sales by source ($m), 2008-14 52

Table 17: Total Cephalon sales by business unit ($m), 2002-08 54

Table 18: Cephalon operating revenue/cost analysis ($m), 2002-08 56

Table 19: Cephalon operating cost ratio analysis (% of total revenues), 2002-08 57

Table 20: Cephalon operating cost ratio analysis (% of total revenues), 2008-14 58

Table 21: Cephalon operating revenue/cost analysis ($m), 2008-14 59

Table 22: Key products overview 61

Table 23: Provigil: overview 62

Table 24: Provigil: sales forecast ($m), 2008-14 63

Table 25: Nuvigil: overview 65

Table 26: Nuvigil: sales forecast ($m), 2008-14 66

Table 27: Actiq: overview 68

Table 28: Actiq: sales forecast ($m), 2008-14 69

Table 29: Fentora: overview 71

Table 30: Fentora: sales forecast ($m), 2008-14 72

Table 31: Treanda: overview 74

Table 32: Treanda: sales forecast ($m), 2008-14 75

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Cephalon prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Cephalon's financial performance ($m), 2002-14 7

Figure 4: Sales of Cephalon's Pain and ESD franchises, 2002-14 ($m) 11

Figure 5: Total sales of the CNS and oncology therapy areas, 2002-14 ($m) 12

Figure 6: Therapy area focus, 2002-14 (%) 14

Figure 7: Cephalon SWOT analysis 16

Figure 8: Cephalon prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 32

Figure 9: Key product sales ($m), 2002-14 34

Figure 10: Cephalon key sales growth drivers and resistors ($m), 2002-08 36

Figure 11: Cephalon key sales growth drivers and resistors ($m), 2008-14 38

Figure 12: Cephalon prescription pharmaceutical sales by therapy area ($m), 2002-14 40

Figure 13: Cephalon prescription pharmaceutical sales by geographic region ($m), 2002-14 42

Figure 14: Cephalon launch/core/expiry configuration ($m), 2008-14 48

Figure 15: Cephalon prescription pharmaceutical sales by molecule type ($m), 2002-14 49

Figure 16: Cephalon prescription pharmaceutical sales by source ($m), 2002-14 51

Figure 17: Cephalon operating revenue/cost analysis ($m), 2002-14 55

To order this report:

Pharmaceutical Industry: Cephalon Inc.: PharmaVitae Profile

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds The Future of Nutrigenomics: New...
S
Reportlinker Adds Shire plc: PharmaVitae Profile